We are proud to announce
The recent FDA approval of the novel breast cancer treatment Enhertu, (an antibody-drug conjugate). This is exciting news for both breast cancer patients and Ironwood Cancer & Research Centers.
Ironwood Cancer & Research Centers were selected to participate in DESTINY2 and DESTINY3 clinical trials to assist in bringing this promising treatment agent to the community. Clinical studies resulted in the approval of Enhertu for both advanced Her2/neu-low breast cancer and advanced Her2/neu positive gastric and gastroesophageal adenocarcinoma.